3-[2-(Di-sec-butyl-amino)-ethyl]-1H-indol-4-ol | 127507-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-[2-(Di-sec-butyl-amino)-ethyl]-1H-indol-4-ol
• 英文别名: 4-HO-Dsbt；3-[2-[di(butan-2-yl)amino]ethyl]-1H-indol-4-ol
• CAS: 127507-01-1
• 化学式: C₁₈H₂₈N₂O
• 分子量: 288.433
• InChiKey: SMKFHUHBZWMALV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  39.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  二仲丁胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 18.25h， 生成 3-[2-(Di-sec-butyl-amino)-ethyl]-1H-indol-4-ol
  参考文献：
  名称：

  硅氧菌素类似物II。3- [2-（二烷基氨基）乙基]-，3- [2-（N-甲基-N-烷基氨基）乙基]-和3- [2-（环烷基氨基）乙基]吲哚-4-醇的合成

  摘要：

  psilocin（3- [2-二甲基氨基）乙基]吲哚-4-醇（12a）的N b-取代基的结构改变导致许多化合物含有已知的药效基团。此外，希望这些取代基的性质的细微变化可以导致对4-羟基色胺致幻剂的结构-活性关系的更清楚的理解。

  DOI：

  10.1002/jhet.5570180131

文献信息

• Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness
  申请人：Dresdner, JR. Karl P.

  公开号：US20200345585A1

  公开（公告）日：2020-11-05

  The invention relates to processes for making pharmaceutical aqueous therapeutic particles (AQTP) having stable exterior water clustering with nanosized thickness less than 300 nanometers, wherein the AQTP has an improved bioavailability when administered to a mammal compared to conventional pharmaceutical drug particles administered to the mammal. The invention relates to an improved process apparatus which is computer controlled, capable of continuous operation with high efficiency so as to make a more consistently acceptable AQTP compared to an previous prototype process apparatus of the Inventors. The invention provides compositions comprising of AQTP which comprise a substance selected from the group consisting of a cannabinoid such as CBD, a cell membrane pore-forming peptide such as PNC-27, a psychoactive drug, a pharmaceutical, a nutraceuticals, a mineral, an anion, a cation, a protein, a peptide, an amino acid, a polymer, a vitamins, an antioxidants, a fertilizer, a chemical, a medical use product, a medical kit use product, a personal consumer use product, a manufacturing use product, a energy use product such as a battery, and any combination thereof.
• Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2-(<i>N</i>-methyl-<i>N</i>-alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols
  作者：David B. Repke、Wilfred J. Ferguson、Dallas K. Bates

  DOI：10.1002/jhet.5570180131

  日期：1981.1

  Structural alteration of the Nb-substituents of psilocin (3-[2-dimethylamino)ethyl]indol-4-ol) (12a) has led to a number of compounds containing known pharmacophoric groups. Further, it is hoped that the subtle changes in the nature of these substituents may lead to a clearer understanding of the structure-activity relationships of the 4-hydroxytryptamine hallucinogens.

  psilocin（3- [2-二甲基氨基）乙基]吲哚-4-醇（12a）的N b-取代基的结构改变导致许多化合物含有已知的药效基团。此外，希望这些取代基的性质的细微变化可以导致对4-羟基色胺致幻剂的结构-活性关系的更清楚的理解。